Stifel Upgrades Repare Therapeutics to Buy, Raises Price Target to $16
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Benjamin Burnett upgraded Repare Therapeutics (NASDAQ:RPTX) from Hold to Buy and raised the price target from $11 to $16.
June 09, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Repare Therapeutics (RPTX) has been upgraded to Buy from Hold by Stifel analyst Benjamin Burnett, with a raised price target of $16 from $11.
The upgrade from Hold to Buy and the increase in price target from $11 to $16 by Stifel analyst Benjamin Burnett indicates a positive outlook for Repare Therapeutics (RPTX) in the short term. This news is likely to have a positive impact on the stock price as it reflects increased confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100